New
Temprian Therapeutics, a spinoff from Northwestern University with patent for DNA-based vitiligo treatment, has made it to the finals of the Nature Spinoff Prize.
The 12 finalists represent companies from the United States, United Kingdom, Switzerland and Spain operating in pharmaceuticals, predictive assays and medical devices. Temprian’s selection as a finalist for the Nature Spinoff Prize provides hope for securing investment needed for a clinical trial.
The judges will select four companies to participate in a live slam on 13 July. The winner will be awarded the title of 2020 Nature Spin-off Prize champion — and a grant of €30,000 (about US$34,000).
Details of Temprian’s innovation and its underlying patent Mutant HSP70i to Prevent Autoimmune Disease.
FAQOther Questions
- How smoking affects vitiligo?
Smoking is a common habit linked to numerous health risks, affecting multiple body systems and increasing various disease risks, including respiratory and cardiovascular issues....
- Can Ayurveda help with vitiligo?
Vitiligo is an autoimmune condition characterized by white patches of skin that can develop and spread unpredictably. While there is no cure, medical treatments and complementar...
- Isn't it just a cosmetic disorder?
Contrary to popular belief, vitiligo is not merely a cosmetic issue but a complex autoimmune disorder that affects the body’s largest organ—along with other vital systems—and is...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.